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Abstract
Background: Chemokines have been reported to play an important role in granulomatous inflammation
during Schistosoma mansoni infection. However there is less information on their role in Schistosoma
haematobium infection, or on the effect of concurrent HIV-1 infection, as a potential modifying influence.
Methods: To determine levels of MIP-1α/CCL3 chemokine in plasma of S. haematobium and HIV-1 co-
infected and uninfected individuals in a rural black Zimbabwean community.
A cohort was established of HIV-1 and schistosomiasis infection and co-infection comprising 379
participants. Outcome measures consisted of HIV-1 and schistosomiasis status and levels of MIP-1α/CCL3
in plasma at baseline and three months post treatment. An association was established between MIP-1α/
CCL3 plasma levels with HIV-1 and S. haematobium infections.
Results: A total of 379 adults formed the established cohort comprising 76 (20%) men and 303 (80%)
women. Mean age was 33.25, range 17 - 62 years. The median MIP-1α/CCL3 plasma concentration was
significantly higher in S. haematobium infected compared with uninfected individuals (p = 0.029). In contrast,
there was no difference in the median MIP-1α/CCL3 levels between HIV-1 positive and negative individuals
(p = 0.631). MIP-1α/CCL3 concentration in plasma was significantly reduced at three months after
treatment with praziquantel (p = 000).
Conclusion: The results of our study show that the MIP-1α/CCL3 levels were positively associated with
S. haematobium egg counts at baseline but not with HIV-1 infection status. MIP-1α/CCL3 levels were
significantly reduced at three months post treatment with praziquantel. We therefore conclude that MIP-
1α/CCL3 is produced during infection with S haematobium. S. haematobium infection is associated with
increased MIP-1α/CCL3 levels in an egg intensity-dependent manner and treatment of S. haematobium is
associated with a reduction in MIP-1α/CCL3.
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Background
Human immunodeficiency virus (HIV)subtype 1, affects
over 25 million persons in sub-Saharan Africa, with most
living without access to antiretroviral treatment [1,2]. An
estimated 200 million persons are infected with schisto-
somes [3,4]. The number of persons co-infected with
these diseases is not known but in some areas the preva-
lence of co-infected persons is estimated to be high [5-9].
In humans, infection with the trematode parasites, S.
mansoni and S. haematobium, is followed, after 4-6 weeks,
by the deposition of eggs in the liver and other body
organs, leading to immune activation [10]. The impact of
schistosomiasis on the progression of HIV in co-infected
persons has been contradictory, with reports from uncon-
trolled studies showing little or no effects of schistosomia-
sis treatment [5-9]. Infection with HIV induces immune
activation with high levels of circulating cytokines, such as
tumor necrosis factor-alpha (TNF-α) [11,12], interleukin-
6 (IL-6) [13,14], IL-10 [13,15,16], and some chemokines
[14,15]. Activated CD4 cells express increased levels of the
co-receptors CCR5 and CXCR4 speculated to enhance HIV
entry and infect host cells [17], and MIP-1α/CCL3
enhances expression of these receptors that are also used
by the virus. In vitro, the cytokines TNF-α and IL-6, as well
as the chemokines IL-8 and MIP-1α/CCL3 can activate
and assist the translocation of the transcription factor
nuclear factor (NF)-κB in monocytes or macrophages
[17]. In uninfected cells, this leads to cell proliferation
and differentiation. However, the HIV provirus DNA car-
ries multiple NF-κB binding sites; thus, the activation of
NF-κB in HIV-infected cells results in viral nucleus mate-
rial translocation into the host nucleus thereby undergo-
ing replication [17]. Conversely, the anti-inflammatory
cytokines IL-10 and TGF-β downregulate the pro-inflam-
matory cytokine TNF-α and MIP-1α/CCL3, thereby inhib-
its HIV replication in vitro in macrophages [17-19].
Schistosomiasis and some helminth infections are known
to induce systemic inflammation associated with
increased activation of CD4 cells and higher levels of CD8
cells [20], including surface receptor expression [21]. The
initial acute schistosomiasis infection is characterized by
production of T helper type 1 (Th1) cytokine that include
interferon-γ and production of Th2 cytokines including
IL-10 that would predominate in the subsequent early
phases of the infection, attributed to play an important
anti-inflammatory role [22-24]. There are few reports
regarding levels of circulating cytokines during HIV and
schistosomiasis co-infection, but Brown et al., (2005)
reported that circulating IL-10 is reduced after treatment
with praziquantel in co-infected persons and production
of other cytokines during HIV-infection might also be
affected by schistosomiasis co-infection [8,25-28]. Greater
concentrations of MIP-1α/CCL3/have been reported in S.
mansoni  infected individuals compared to uninfected
individuals [8]. Plasma levels of MIP-1α/CCL3 have also
been investigated and reported in several studies of S man-
soni infected humans, murine models [24] and cell culture
infections [27,28], but none for S. haematobium. The aim
of our study was to determine the plasma MIP-1α/CCL3
concentration in S. haematobium infected and uninfected
humans at baseline and at three months after treatment
with praziquantel and the influence of HIV-1 co-infection.
We hypothesized that schistosomiasis would induce sys-
temic inflammation indicated by the levels of circulating
soluble MIP-1α/CCL3, a proinflammatory chemokine,
and observed the effects of schistosomiasis treatment with
praziquantel.
Methods
Setting and study population
The study was conducted from October 2001 to June 2003
in Mupfure and adjacent areas in Shamva District, Mash-
onaland Central Province, Zimbabwe. This rural area is
characterized by subsistence farming, and the main source
of water for irrigation, bathing, and washing is the Mup-
fure River, which is infested mainly by Bulinus  species
snails but also by Biomphalaria  species snails [29]. No
schistosomiasis control program has previously targeted
the adult population of the area. The study population
was composed of adults (>18 years old) residing in the
area who were willing to submit urine, stool, and blood
samples and to be tested for HIV-1. Recruitment of partic-
ipants was achieved through community meetings and
was facilitated by local village health workers. The Medi-
cal Research Council of Zimbabwe and the Central Medi-
cal Scientific Ethics Committee of Denmark approved the
study, and informed consent was obtained from all partic-
ipants. In addition, permission was given by the provin-
cial medical director of Mashonaland Central Province,
the district medical officer of Shamva District, and the vil-
lage leaders.
Screening procedure for HIV-1 serological and 
parasitological testing
Screening procedures were performed on all willing par-
ticipants. HIV-1 testing was performed confidentially. Pre-
test and post-test counseling was provided in the
participants' native language (Shona) by qualified person-
nel. In the field, a rapid HIV-1/2 test kit was used (Deter-
mine; Abbott Laboratories). All individuals who were
initially found to be HIV-1 positive were retrospectively
retested using a different rapid test kit (Oraquick by
Orasure Technologies, Serodia by Fujirebio, or Capillus
by Trinity Biotech). For participants subsequently
included in the cohort, 2 ELISAs were performed on
serum samples; No discrepancies were found between the
results of the initial rapid HIV-1/2 test and those of the 2
subsequent ELISAs. Microscopic examination of fixed-vol-
ume urine samples filtered on Nytrel filters (VesterGaardBMC Infectious Diseases 2009, 9:174 http://www.biomedcentral.com/1471-2334/9/174
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Frandsen) was used to identify and quantitate eggs of S.
haematobium  by the syringe urine filtration technique
[30]. Because of the diurnal and day-today variation in egg
output, the urine samples were collected on 3 consecutive
days [31]. The modified formol-ether concentration tech-
nique was used on 1 stool sample from each participant
to detect eggs of S. mansoni and other helminth or para-
sites [32].
Establishment of cohort
After the screening procedure, HIV-1-infected individuals
who were coinfected with Schistosoma  parasites were
included in a prospective cohort. Simultaneously, a
number of HIV-1-negative but schistosomiasis-positive
individuals were included as controls, as were individuals
infected only with HIV-1 and individuals with neither
infection. The 379 participants included in the cohort
were interviewed to obtain sociodemographic data and
medical history, and a clinical examination was per-
formed. Exclusion criteria were applied to participants
presenting with clinical signs/symptoms of tuberculosis
or severe anemia, but no participants were excluded for
these reasons. Pregnant women were excluded from the
study but were diagnosed and offered praziquantel as
treatment for schistosomiasis after delivery and termina-
tion of breast-feeding.
Blood sampling and MIP-1α/CCL3 assay
Blood was drawn into EDTA-coated tubes and kept cool
until separation within a maximum of four hours after
sampling. Plasma was transferred to cryotubes and stored
in liquid nitrogen until shipment to laboratory, samples
were stored at -80°C until analysis. Plasma levels of MIP-
1α/CCL3 were assessed by an ELISA (Quantikine; R&D
Systems, Minneapolis, MN) as described by the manufac-
turer [33]. Briefly, a double-sandwich ELISA in which
MIP-1α/CCL3 was detected using a capture mouse anti
human MIP-1α/CCL3 monoclonal antibody and a bioti-
nylated goat anti-human MIP-1α/CCL3 antibody. The
chemokine concentrations were determined in duplicate
using a standard curve obtained from the known concen-
tration of cytokine standards included in each assay plate
within the range 15 pg/ml - 2000 pg/ml.
Statistical analysis
All statistical analyses were performed using SPSS soft-
ware (version 8.2). Egg counts were log-transformed to
approximate normal distribution. Results from egg counts
were used to stratify the schistosomiasis status of the par-
ticipants into subgroups (no schistosomiasis, infection
with S. haematobium only and co-infection with HIV-1. A
2-way analysis of variance (ANOVA), with HIV-1 status
and schistosomiasis status as classifying variables, was
used to identify differences between groups with respect
to egg counts, age, and MIP-1α/CCL3, to explore the mag-
nitude of the egg infection intensity effect on MIP-1α/
CCL3. A t test was performed to evaluate differences in egg
counts between HIV-1 groups and was complemented
with an analysis of covariance (ANCOVA) to allow for
adjustments according to age and sex. The magnitude of
effects was evaluated by back transformation of the log-
transformed difference in means and 95% confidence
intervals (CIs) between groups. P < 0.05 was considered to
be significant.
Results
A total of 1545 individuals were screened by 3 consecutive
urine samples, 1 stool sample, and information on HIV-1
status for recruitment of the 379 individuals into the
cohort. Overall, 26.3% were HIV-1 positive, similar figure
to the national prevalence levels [34]; 43.4% had schisto-
somiasis, and there were no differences in distribution of
schistosome infections according to HIV-1 status (Table
1). The prevalence of other helminth infections was negli-
gible and as reported previously [7,33,35]; very few indi-
viduals were diagnosed with Taenia saginata (n  = 2),
Strongyloides stercoralis (n = 2), or Trichuris trichiura (n = 1).
Other identified intestinal parasites were the protozoans
Entamoeba histolytica (n = 54; 47 [4.7%] were HIV-1 nega-
tive participants and 7 [1.7%] were HIV-1 positive partic-
ipants; P < 0.05) and Giardia lamblia (n = 9; 8 were HIV-1
negative participants and 1 was an HIV-1 positive partici-
pant). Table 1 presents the sex and age distribution of the
cohort. However, predominantly women participated in
the study (75%), and there were no differences in sex dis-
tribution across the subgroups according to HIV-1 status
or schistosomiasis status. Detailed results of the recruited
individuals on interaction of schistosomiasis and HIV-1
are reported elsewhere [35]. The t test comparing urine
egg counts confirmed no difference according to HIV-1
status for S. haematobium infected participants (P = 0.51;
mean HIV-1 positive participants: HIV-1 negative partici-
pants, 0.91; 95% CI, 0.67-1.22). Of the 379 participants
included in the prospective cohort, complete baseline
information was available on all and the characteristics of
the cohort population and the distribution of the schisto-
some and HIV-1 infections are presented in Table 1. There
were no differences in egg counts attributable to either the
interaction between HIV-1 and schistosomiasis or to HIV-
1 status or schistosomiasis status separately.
Plasma concentrations of MIP-1α/CCL3 were available on
all 379 cohort participants for the baseline before treat-
ment and on 83 selected at three months post treatment.
The median MIP-1α/CCL3 plasma concentration was sig-
nificantly higher in S haematobium infected compared
with uninfected individuals (S. haematobium positive 171
pg/ml, S. haematobium negative 39 pg/ml (p = 0.0029)
(Table 1, Figure 1). There was no difference in the median
MIP-1α/CCL3 levels between HIV-1 positive and HIV-1BMC Infectious Diseases 2009, 9:174 http://www.biomedcentral.com/1471-2334/9/174
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negative individuals (HIV negative 139 pg/ml, HIV posi-
tive 124 pg/ml, (p = 0.6312). In the 198 HIV-1 infected
participants, MIP-1α/CCL3 concentration did not differ
between participants with CD4 T-cell counts of 0.1 × 109/
L or more and those with counts below this value (Mann-
Whitney test, p = 0.4993). There was no correlation
between MIP-1α/CCL3 concentration and the CD4 T-cell
counts (Spearman's r = 0.0039, p = 0.956).
On accounting for the four schistosomiasis infection
intensity groups, there was a statistically significant differ-
ence between the four infection groups, p = 0008, mainly
Table 1: The characteristics of the study cohort in the S. haematobium and HIV-1 co-infection
Variable n Median MIP-1α/CCL3 (pg/ml) (Interquartile range) p-value
Sex
Male 76 144 (65 - 295)
Female 303 127 (56 - 205) 0.2130
Total 379
S. haematobium
Positive 263 171 (132 - 630)
Negative 116 39 (4 - 90) 0.0029
HIV status
Positive 198 124 (36 - 550)
Negative 181 139 (47 - 445) 0.6312
Age (years)
< 25 82 166 (55 - 525)
≥ 25 297 121 (35 - 595) 0.2570
Age groups (years)
< 20 24 146 (66 - 378)
20 - 29 156 135 (78 - 402)
30 - 39 92 113 (46 - 399)
40 - 49 76 126 (72 - 332)
50 + 31 163 (33 - 298) 0.5060
Co-infection status
HIV+ S. haematobium + 154 144 (124 - 447)
HIV- S. haematobium + 130 177 (133 - 506)
HIV+ S. haematobium - 48 64 (6 - 79)
HIV- S. haematobium - 47 30 (3 - 57) 0.0008
CD4 vs MIP-1a/CCL3 in HIV+
Above 250 180 120 (38 - 440)
Below 250 18 156 (36 - 398) 0.4993
Eggs per 10 ml urine
0 116 36 (5 - 81)
<10 177 80 (66 - 168)
10 - <50 77 379 (211 - 680)
>50 9 333 (199 - 862) 0.0001
Time point
Baseline (before treatment) 263 131 (102 - 560)
3 months post treatment 83 71 (6 - 94) 0.0001
Given are the medians and interquartile ranges of levels of plasma MIP-1α/CCL3 chemokine. The MIP-1α/CCL3 was measured in pg/ml using 
double sandwich ELISA within the range 15 pg/ml - 2000 pg/ml. Results from egg counts were used to stratify the schistosomiasis status of the 
participants into subgroups (no schistosomiasis, infection with S. haematobium only and co-infection with HIV-1. HIV-1 status and schistosomiasis 
status as classifying variables was used to identify differences between groups with respect to egg counts, age, and MIP-1α/CCL3; and p < 0.05 was 
considered to be significant.BMC Infectious Diseases 2009, 9:174 http://www.biomedcentral.com/1471-2334/9/174
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due to the differences between individuals with S. haema-
tobium infection and the uninfected. Also a statistically sig-
nificant difference was observed in MIP-1α/CCL3 levels in
an egg intensity-dependent manner, individuals with less
than 10 eggs per 10 ml of urine having significantly lower
MIP-1α/CCL3 than individuals with more than 10 eggs
per 10 ml urine (Table 1, Figure 2). No difference in
median MIP-1α/CCL3 concentration was observed
between males and females, (males 127 pg/ml, females
144 pg/ml (p = 0.2133). Also no difference in median
MIP-1α/CCL3 concentration was noted when the cohort
was stratified into two age groups, below and above 25
years, p = 0.2570, and into five age groups, p = 0.3537
(Table 1).
Eighty-three (83) samples were analysed for MIP-1α/
CCL3 at three months post treatment. Sixty one S. haema-
tobium positive and 22 controls were selected for the post
treatment analyses, only from individuals who received
praziquantel treatment at baseline. Samples with high S.
haematobium egg counts at baseline were prioritized for
post treatment analysis, these were from individuals
excreting more than 50 eggs/10 ml as heavy infection,
within 10-50 eggs/10 ml as moderate infection intensity
and from individuals excreting less than 10 eggs/10 ml as
light infection. A comparison was done on the median
MIP-1α/CCL3 concentration on samples from the same
participants at baseline and at 3 months post treatment.
The median MIP-1α/CCL3 concentration in plasma was
significantly reduced at three months post treatment com-
pared to baseline levels (Wilcoxon signed rank test, p =
0000, Figure 3).
Discussion
Schistosomiasis and HIV-1 co-infection has been
observed from a couple of studies in Zimbabwe and else-
where to have far reaching consequences, especially in
likelihood of immunopathology and AIDS progression
[5-9]. However, no clear attributive aspects have been
linked or are known to worsen the condition during co-
infection. Generally, in addition to cytokines, chemokines
also play an important role in the regulation of immune
responses and in controlling infectious diseases including
HIV infection and progression. Cytokine and chemokines
are chemotactic for specific types of cells and are involved
in immunoregulation of cell mediated immunity. MIP-
1α/CCL3 play an important role in recruiting macro-
phages, dendritic cells and T cells to site of infection and
lymphoid organs, a task perceived to likely contribute to
the dangers of schistosomiasis and HIV-1 co-infection. In
this study we found that schistosomiasis infection being
depicted by high egg output significantly upregulated the
Box-whisker plot of MIP-1α/CCL3 concentrations comparing S. haematobium infected and uninfected individuals Figure 1
Box-whisker plot of MIP-1α/CCL3 concentrations comparing S. haematobium infected and uninfected individu-
als.
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plasma levels of MIP-1α/CCL3 irrespective of HIV-1 infec-
tion status. Some studies have identified MIP-1α/CCL3 as
a marker of disease severity in S. mansoni infected individ-
uals [11,25] and experimental studies in mice suggest that
MIP-1α/CCL3 may be a causative factor in the develop-
ment of severe schistosomiasis [24]. We investigated lev-
els of MIP-1α/CCL3 in the plasma of HIV-1 and S.
haematobium infected and uninfected individuals. These
diseases are endemic in Zimbabwe where it is common to
find individuals with HIV-1 and a parasitic co-infection.
From the observation on the co-infection data no differ-
ences in egg counts were found between HIV-1 positive
participants and HIV-1 negative participants infected with
S. haematobium. The findings were reported in detail by
our group Kallestrup et al., (2005) [7]. However, briefly,
the findings on the coinfection data on schistosomiasis
egg counts reveal similarity between HIV-1 coinfected
even after adjustments were made for differences in age
and sex. These findings, led to speculation of an immu-
nomodulatory inhibition of the human host's ability to
excrete Schistosoma eggs when immunodeficient because
of HIV-1 coinfection [35]. The findings indicated moder-
ately to severely immunocompromised individuals whose
interactions between HIV-1 and concurrent infections
with S. haematobium indicated by higher egg counts cause
inflammation during schistosomiasis. This finding is in
agreement with other reports of an association between
CD4 lymphocytopenia and helminthic and other infec-
tions [22,36-40]. These differences in CD4 cell counts
apparently disappear in S. mansoni infected HIV-1 positive
participants, indicating that any possible subtle effect of
schistosomiasis on CD4 cell counts seems to be masked
by the dramatic HIV-1 related decline in CD4 cell counts
[35]. Despite the difference between the intensities of the
S. haematobium infections in the population in the study
and the S. mansoni infection in other studies, it appears
that HIV-1 induced immunodeficiency does not impair
the ability of participants with low and high intensity
schistosomiasis to excrete S. haematobium eggs. Our results
as first reported in Kallestrup et al., (2005) [7], further
question the applicability of murine studies that show a
dependency of adequate CD4 cell immunity for S. man-
soni  development and fecundity to human conditions.
One may assume that, in our cohort, some antischisto-
some immune responses were already established when
HIV-1 was encountered [7,22].
Box-whisker plot of MIP-1α/CCL3 concentrations according to S. haematobium egg intensity, the classification is based on the  WHO classification of; 0 = uninfected, < 10 eggs/10 ml of urine = light infection, 10 to <50 eggs/10 ml = moderate infection  and more than 50 eggs/10 ml = high infection Figure 2
Box-whisker plot of MIP-1α/CCL3 concentrations according to S. haematobium egg intensity, the classification 
is based on the WHO classification of; 0 = uninfected, < 10 eggs/10 ml of urine = light infection, 10 to <50 eggs/
10 ml = moderate infection and more than 50 eggs/10 ml = high infection. The egg infection intensity was deter-
mined by the urine filtration technique in 10 ml of urine collected over three consecutive days.
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Schistosoma haematobium infected individuals had elevated
levels of MIP-1α/CCL3 compared with egg negative indi-
viduals. This is in agreement with findings by other inves-
tigators on S. mansoni infection who demonstrated a
positive correlation between elevated plasma concentra-
tions of MIP-1α/CCL3, egg counts and presentation of
severe schistosomiasis in humans [22-25]. Our results
also showed that HIV-1 status had no influence on the lev-
els of MIP-1α/CCL3 as individuals who were HIV-1 posi-
tive and S. haematobium positive had similar elevated
levels as those who were HIV-1 negative and S. haemato-
bium positive, suggesting that schistosomiasis infection is
causing the elevation of MIP-1α/CCL3 levels. This is fur-
ther confirmed by a comparison of MIP-1α/CCL3 levels in
HIV-1 positive but S. haematobium negative compared to
HIV-1 negative and S. haematobium negative, both groups
showing low levels of MIP-1α/CCL3. Egg counts also had
an influence on MIP-1α/CCL3 levels as shown by a com-
parison of the four groups which showed elevated levels
in individuals with more than 10 eggs per 10 ml of urine
compared to individuals with less than 10 eggs per 10 ml
of urine. These findings indicated the existence of inflam-
matory environment during infection and egg laying by
the schistosome worms. However, high egg output may
be related to heavy worm burden subsequently related to
increased inflammation by the high egg numbers released
into the system.
We further determined the plasma concentration of MIP-
1α/CCL3 at three months post treatment with the anti-
schistosome drug, praziquantel. MIP-1α/CCL3 concentra-
tion in plasma was significantly reduced at three months
post treatment, an indication that MIP-1α/CCL3 may be
an inflammatory factor produced during S. haematobium
infection and is downregulated when the infection is
eliminated. Similar findings were reported in murine
models [34]. It is assumed that eggs are the stimulant of
this inflammatory response, and we may speculate that
during inflammation, individuals co-infected with HIV-1
may be prone to immune activation and an increase in cir-
culating viruses thereby increase chances of transmission.
This calls for surveillance and control of schistosomiasis
in population living in endemic areas, making praziquan-
tel readily available for the control of schistosomiasis
infection.
Conclusion
The findings from this study have shown that the MIP-1α/
CCL3 chemokine levels were associated with S. haemato-
bium egg counts at baseline before treatment, but not with
HIV-1 infection status. MIP-1α/CCL3 levels were signifi-
Box-whisker plot of MIP-1α/CCL3 concentrations comparing baseline and three months post treatment with praziquantel Figure 3
Box-whisker plot of MIP-1α/CCL3 concentrations comparing baseline and three months post treatment with 
praziquantel. The levels of MIP-1α/CCL3 were measured by ELISA using a standard curve within the detection range of 15 
pg/ml - 2000 pg/ml.
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cantly reduced at three months post treatment with prazi-
quantel. We therefore conclude that MIP-1α/CCL3
chemokine is produced during inflammation, caused by
eggs during S haematobium infection, in which infection is
associated with increased MIP-1α/CCL3 levels in an egg
intensity-dependent manner. Praziquantel treatment of S.
haematobium is associated with a reduction in levels of
MIP-1α/CCL3.
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